DE69739172D1
(de)
|
1996-08-08 |
2009-01-29 |
Amylin Pharmaceuticals Inc |
Regulation gastrointestinaler beweglichkeit
|
US6458924B2
(en)
|
1996-08-30 |
2002-10-01 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
JP3149958B2
(ja)
*
|
1996-08-30 |
2001-03-26 |
ノボ ノルディスク アクティーゼルスカブ |
Glp―1誘導体
|
US6268343B1
(en)
|
1996-08-30 |
2001-07-31 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
US7235627B2
(en)
|
1996-08-30 |
2007-06-26 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
UA65549C2
(uk)
|
1996-11-05 |
2004-04-15 |
Елі Ліллі Енд Компані |
Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
|
US6380357B2
(en)
|
1997-12-16 |
2002-04-30 |
Eli Lilly And Company |
Glucagon-like peptide-1 crystals
|
WO1999043707A1
(en)
|
1998-02-27 |
1999-09-02 |
Novo Nordisk A/S |
N-terminally modified glp-1 derivatives
|
ATE466027T1
(de)
|
1998-02-27 |
2010-05-15 |
Novo Nordisk As |
Abkömmlinge von glp-1 analogen
|
AU2610599A
(en)
*
|
1998-02-27 |
1999-09-15 |
Novo Nordisk A/S |
N-terminally truncated glp-1 derivatives
|
ATE466026T1
(de)
*
|
1998-02-27 |
2010-05-15 |
Novo Nordisk As |
Derivate von glp-1 und exendin mit verlängertem wirkdauer-profil
|
AU3247799A
(en)
*
|
1998-02-27 |
1999-09-15 |
Novo Nordisk A/S |
Glp-1 derivatives of glp-1 and exendin with protracted profile of action
|
ATE265224T1
(de)
*
|
1998-02-27 |
2004-05-15 |
Novo Nordisk As |
Glp-1 derivate mit einem helix-gehalt über 25 , die partiell strukturierte mizellenartige aggregate bilden
|
WO1999046283A1
(en)
|
1998-03-09 |
1999-09-16 |
Zealand Pharmaceuticals A/S |
Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
|
EP1306091A3
(en)
*
|
1998-07-31 |
2003-05-21 |
Novo Nordisk A/S |
Stimulation of beta cell proliferation
|
HUP0103369A3
(en)
*
|
1998-08-28 |
2002-03-28 |
Lilly Co Eli |
Use of insulinotropic peptides
|
EP1666054A1
(en)
*
|
1998-08-28 |
2006-06-07 |
Eli Lilly & Company |
Method for administering insulinotropic peptides
|
US6720407B1
(en)
|
1998-08-28 |
2004-04-13 |
Eli Lilly And Company |
Method for administering insulinotropic peptides
|
CA2343268A1
(en)
|
1998-09-17 |
2000-03-23 |
Eli Lilly And Company |
Protein formulations
|
MY155270A
(en)
*
|
1998-09-24 |
2015-09-30 |
Lilly Co Eli |
Use of glp-1 or analogs in treatment of stroke
|
DK1137666T5
(da)
*
|
1998-12-07 |
2009-10-05 |
Univ Tulane |
GLP-1-analoger
|
CN1935839B
(zh)
*
|
1998-12-07 |
2012-06-06 |
益普生制药股份有限公司 |
胰高血糖素样肽-1的类似物
|
CZ295768B6
(cs)
*
|
1998-12-07 |
2005-10-12 |
Societe De Conseils De Recherches Et D'application |
Analogy GLP-1, mající beta-alanin na pozici 35, jejich použití a farmaceutické prostředky je obsahující
|
NZ512663A
(en)
*
|
1999-01-14 |
2004-05-28 |
Amylin Pharmaceuticals Inc |
Novel exendin agonist formulations and methods of administration thereof
|
US6444788B1
(en)
|
1999-03-15 |
2002-09-03 |
Novo Nordisk A/S |
Ion exchange chromatography of GLP-1, analogs and derivatives thereof
|
US6451987B1
(en)
|
1999-03-15 |
2002-09-17 |
Novo Nordisk A/S |
Ion exchange chromatography of proteins and peptides
|
WO2000055203A1
(en)
|
1999-03-15 |
2000-09-21 |
Novo Nordisk A/S |
Ion exchange chromatographic separation of glp-1 and related peptides
|
KR20020002480A
(ko)
*
|
1999-03-17 |
2002-01-09 |
한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 |
펩티드의 아실화법 및 신규한 아실화제
|
US6451974B1
(en)
|
1999-03-17 |
2002-09-17 |
Novo Nordisk A/S |
Method of acylating peptides and novel acylating agents
|
HUP0200297A3
(en)
*
|
1999-03-17 |
2002-09-30 |
Novo Nordisk As |
Method for acylating peptides and the glutaminic acid derivatives as acylating agents
|
AU775063C
(en)
*
|
1999-04-30 |
2005-05-12 |
Amylin Pharmaceuticals, Inc. |
Modified exendins and exendin agonists
|
US6924264B1
(en)
|
1999-04-30 |
2005-08-02 |
Amylin Pharmaceuticals, Inc. |
Modified exendins and exendin agonists
|
US6514500B1
(en)
|
1999-10-15 |
2003-02-04 |
Conjuchem, Inc. |
Long lasting synthetic glucagon like peptide {GLP-!}
|
CA2501421A1
(en)
|
1999-05-17 |
2000-11-23 |
Conjuchem Inc. |
Long lasting exendin-4
|
EP1076066A1
(en)
*
|
1999-07-12 |
2001-02-14 |
Zealand Pharmaceuticals A/S |
Peptides for lowering blood glucose levels
|
US6528486B1
(en)
|
1999-07-12 |
2003-03-04 |
Zealand Pharma A/S |
Peptide agonists of GLP-1 activity
|
EP1239871A1
(en)
*
|
1999-11-12 |
2002-09-18 |
Novo Nordisk A/S |
Use of glp-1 agonists for the inhibition of beta cell degeneration
|
US6569832B1
(en)
|
1999-11-12 |
2003-05-27 |
Novo Nordisk A/S |
Inhibition of beta cell degeneration
|
US6844321B2
(en)
*
|
2000-01-31 |
2005-01-18 |
Novo Nordisk A/S |
Crystallization of a GLP-1 analogue
|
ES2253353T3
(es)
|
2000-03-08 |
2006-06-01 |
Novo Nordisk A/S |
Reduccion del colesterol serico.
|
DE10013895A1
(de)
|
2000-03-21 |
2001-10-04 |
Dmc2 Degussa Metals Catalysts Cerdec Ag |
Verfahren zur katalytischen Umsetzung von Kohlenmonoxid in einem Wasserstoff enthaltenden Gasgemisch
|
EP1305338A2
(en)
*
|
2000-08-02 |
2003-05-02 |
Theratechnologies Inc. |
Modified peptides with increased potency
|
CA2430934C
(en)
|
2000-12-01 |
2011-06-21 |
Takeda Chemical Industries, Ltd. |
A method of producing sustained-release preparations of a bioactive substance using high-pressure gas
|
UA81897C2
(uk)
*
|
2000-12-07 |
2008-02-25 |
Эли Лилли Энд Компани |
Гетерологічний пептидильований глюкагон-1-подібний білок та його застосування для для виготовлення лікарського засобу для лікування пацієнтів, що страждають на ожиріння та/або інсулінонезалежний діабет
|
JP2004516289A
(ja)
|
2000-12-21 |
2004-06-03 |
アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
ジフェニルアゼチジノン誘導体、その調製方法、その化合物を含む薬剤およびその使用
|
BR0116325A
(pt)
|
2000-12-21 |
2003-10-14 |
Aventis Pharma Gmbh |
1,2-difenilazetidinonas, processos para a sua preparação, medicamentos contendo estes compostos e sua aplicação para o tratamento de distúrbios do metabolismo de lipìdios
|
EP1949908A1
(en)
|
2001-03-07 |
2008-07-30 |
Novo Nordisk A/S |
Combined use of derivatives of GLP-1 analogs and PPAR ligands
|
US6573237B2
(en)
|
2001-03-16 |
2003-06-03 |
Eli Lilly And Company |
Protein formulations
|
US8981061B2
(en)
|
2001-03-20 |
2015-03-17 |
Novo Nordisk A/S |
Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
|
DE10142660A1
(de)
|
2001-08-31 |
2003-03-20 |
Aventis Pharma Gmbh |
Verwendung von Derivaten von C2-substituierten Indan-1-ol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
|
US6653492B2
(en)
|
2001-05-02 |
2003-11-25 |
Novo Nordick A/S |
Preparation of bile acids
|
EP1698636A1
(en)
*
|
2001-05-02 |
2006-09-06 |
Novo Nordisk A/S |
Preparation of derivatized peptides from bile acids
|
PE20021091A1
(es)
|
2001-05-25 |
2003-02-04 |
Aventis Pharma Gmbh |
Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
|
DK1412384T3
(da)
*
|
2001-06-28 |
2008-04-28 |
Novo Nordisk As |
Stabil formulering af modificeret GLP-1
|
US20030082671A1
(en)
|
2001-07-24 |
2003-05-01 |
Thomas Hoeg-Jensen |
Method for making acylated polypeptides
|
US7595172B2
(en)
*
|
2001-07-24 |
2009-09-29 |
Novo Nordisk A/S |
Method for making acylated polypeptides
|
JP2005501861A
(ja)
|
2001-08-22 |
2005-01-20 |
アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
1,4−ベンゾチエピン1,1−ジオキシド誘導体と他の活性物質との組合わせ剤及びそれらの使用
|
DE10142666A1
(de)
|
2001-08-31 |
2003-03-20 |
Aventis Pharma Gmbh |
Verwendung von C2-substituierten Indan-1-ol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
|
US6884812B2
(en)
|
2001-08-31 |
2005-04-26 |
Aventis Pharma Deutschland Gmbh |
Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals
|
DE10142659A1
(de)
|
2001-08-31 |
2003-03-20 |
Aventis Pharma Gmbh |
Verwendung von mehrfach substituierten Indan-1-ol. Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
|
US7399777B2
(en)
|
2001-08-31 |
2008-07-15 |
Sanofi-Aventis Deutschland Gmbh |
Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
|
ATE347890T1
(de)
|
2001-08-31 |
2007-01-15 |
Sanofi Aventis Deutschland |
Diarylcycloalkylderivate, verfahren zu ihrer herstellung und ihre verwendung als ppar- aktivatoren
|
DE10142662B4
(de)
|
2001-08-31 |
2004-07-08 |
Aventis Pharma Deutschland Gmbh |
Derivate von C2-substituierten Indan-1-ol-Systemen und ihre Verwendung als Arzneimittel
|
DE10142663B4
(de)
|
2001-08-31 |
2004-08-19 |
Aventis Pharma Deutschland Gmbh |
C2-Disubstituierte Indan-1-ol-Systeme
|
DE10142665B4
(de)
|
2001-08-31 |
2004-05-06 |
Aventis Pharma Deutschland Gmbh |
C2-Disubstituierte Indan-1-one und ihre Derivate
|
DE10142661B4
(de)
|
2001-08-31 |
2004-06-09 |
Aventis Pharma Deutschland Gmbh |
Mehrfach substituierte Indan-1-ol-Systeme und ihre Verwendung als Arzneimittel
|
DE10142667B4
(de)
|
2001-08-31 |
2004-06-09 |
Aventis Pharma Deutschland Gmbh |
C2-substituierte Indan-1-ole und ihre Derivate und ihre Verwendung als Arzneimittel
|
DE10142668A1
(de)
|
2001-08-31 |
2003-03-20 |
Aventis Pharma Gmbh |
Verwendung von C2-substituierten Indan-1-on-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
|
DE10142722A1
(de)
|
2001-08-31 |
2003-03-27 |
Aventis Pharma Deutschland GmbH, 65929 Frankfurt |
C2-substituierte Indan-1-one und ihre Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
CN100350968C
(zh)
|
2001-09-24 |
2007-11-28 |
皇家创新有限公司 |
饮食行为的改进
|
WO2003031432A1
(en)
|
2001-10-12 |
2003-04-17 |
Novo Nordisk A/S |
Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor
|
RU2353625C2
(ru)
*
|
2001-10-18 |
2009-04-27 |
Бристол-Маерс Сквибб Компани |
Миметики человеческого глюканоподобного пептида-1 и их применение в лечении диабета и родственных состояний
|
US7238671B2
(en)
|
2001-10-18 |
2007-07-03 |
Bristol-Myers Squibb Company |
Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
|
CZ2004747A3
(cs)
|
2001-12-21 |
2004-11-10 |
Novo Nordisk A/S |
Deriváty amidů jako GK aktivátory
|
JP2005518408A
(ja)
|
2001-12-29 |
2005-06-23 |
ノボ ノルディスク アクティーゼルスカブ |
異常脂肪血症を治療するための、glp−1化合物と他の薬物との組み合わせ使用
|
AU2003200839B2
(en)
*
|
2002-01-08 |
2008-12-11 |
Eli Lilly And Company |
Extended glucagon-like peptide-1 analogs
|
WO2003057235A2
(en)
*
|
2002-01-10 |
2003-07-17 |
Imperial College Innovations Ltd |
Modification of feeding behavior
|
US8058233B2
(en)
|
2002-01-10 |
2011-11-15 |
Oregon Health And Science University |
Modification of feeding behavior using PYY and GLP-1
|
RU2332229C2
(ru)
|
2002-02-20 |
2008-08-27 |
Эмисфире Текнолоджис Инк. |
Способ введения молекул glp-1
|
US7223796B2
(en)
|
2002-04-11 |
2007-05-29 |
Sanofi-Aventis Deutschland Gmbh |
Acyl-4-carboxyphenylurea derivatives, processes for preparing them and their use
|
US7049341B2
(en)
|
2002-06-07 |
2006-05-23 |
Aventis Pharma Deutschland Gmbh |
N-benzoylureidocinnamic acid derivatives, processes for preparing them and their use
|
US7671047B2
(en)
|
2002-06-19 |
2010-03-02 |
Sanofi-Aventis Deutschland Gmbh |
Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
|
US7176193B2
(en)
|
2002-06-19 |
2007-02-13 |
Sanofi-Aventis Deutschland Gmbh |
Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
|
US7176194B2
(en)
|
2002-06-19 |
2007-02-13 |
Sanofi-Aventis Deutschland Gmbh |
Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
|
MXPA05000130A
(es)
|
2002-06-27 |
2005-02-17 |
Novo Nordisk As |
Derivados de aril-carbonilo como agentes terapeuticos.
|
ATE432289T1
(de)
*
|
2002-07-04 |
2009-06-15 |
Zealand Pharma As |
Glp-1 und behandlungsmethode für diabetes
|
US7262220B2
(en)
|
2002-07-11 |
2007-08-28 |
Sanofi-Aventis Deutschland Gmbh |
Urea- and urethane-substituted acylureas, process for their preparation and their use
|
DE10231370B4
(de)
|
2002-07-11 |
2006-04-06 |
Sanofi-Aventis Deutschland Gmbh |
Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
|
PL373329A1
(en)
|
2002-07-12 |
2005-08-22 |
Sanofi-Aventis Deutschland Gmbh |
Heterocyclically substituted benzoylureas, method for their production and their use as medicaments
|
US7141561B2
(en)
|
2002-07-25 |
2006-11-28 |
Sanofi-Aventis Deutschland Gmbh |
Substituted diaryl heterocycles, process for their preparation and their use as medicaments
|
US8821915B2
(en)
|
2002-08-09 |
2014-09-02 |
Veroscience, Llc |
Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
|
KR101131783B1
(ko)
*
|
2002-09-25 |
2012-03-30 |
노보 노르디스크 에이/에스 |
아실화된 펩타이드의 제조방법
|
US7273921B2
(en)
|
2002-09-25 |
2007-09-25 |
Novo Nordisk A/S |
Method for producing acylated peptides
|
AU2003271452A1
(en)
*
|
2002-09-25 |
2004-04-19 |
Theratechnologies Inc. |
Modified glp-1 peptides with increased biological potency
|
US20040157922A1
(en)
|
2002-10-04 |
2004-08-12 |
Aventis Pharma Deutschland Gmbh |
Carboxyalkoxy-substituted acyl-carboxyphenylurea derivatives and their use as medicaments
|
US7208504B2
(en)
|
2002-10-12 |
2007-04-24 |
Sanofi-Aventis Deutschland Gmbh |
Bicyclic inhibitors of hormone sensitive lipase
|
US7411039B2
(en)
|
2002-10-14 |
2008-08-12 |
Novo Nordisk A/S |
GLP-2 compounds, formulations, and uses thereof
|
DE10258007B4
(de)
|
2002-12-12 |
2006-02-09 |
Sanofi-Aventis Deutschland Gmbh |
Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
|
US7655618B2
(en)
|
2002-12-27 |
2010-02-02 |
Diobex, Inc. |
Compositions and methods for the prevention and control of insulin-induced hypoglycemia
|
WO2004060387A1
(en)
|
2002-12-27 |
2004-07-22 |
Diobex, Inc. |
Compositions and methods for the prevention and control of insulin-induced hypoglycemia
|
GB0300571D0
(en)
|
2003-01-10 |
2003-02-12 |
Imp College Innovations Ltd |
Modification of feeding behaviour
|
US20040242583A1
(en)
|
2003-01-20 |
2004-12-02 |
Aventis Pharma Deutschland Gmbh |
Pyrimido[5,4-e][1,2,4]triazine-5,7-diones, processes for preparing them and their use
|
US7179941B2
(en)
|
2003-01-23 |
2007-02-20 |
Sanofi-Aventis Deutschland Gmbh |
Carbonylamino-substituted acyl phenyl urea derivatives, process for their preparation and their use
|
EP1592471B1
(en)
|
2003-02-04 |
2011-03-23 |
Novo Nordisk A/S |
Injection device with rotatable dose setting mechanism
|
US7652007B2
(en)
|
2003-02-13 |
2010-01-26 |
Sanofi-Aventis Deutschland Gmbh |
Nitrogen-substituted hexahydropyrazino[1,2-A]pyrimidine-4,7-dione derivatives, processes for their preparation and their use as medicaments
|
US7390814B2
(en)
|
2003-02-13 |
2008-06-24 |
Sanofi-Aventis Deutschland Gmbh |
Substituted hexahydropyrazino [1,2-a] pyrimidine-4,7-dione derivatives, process for their preparation and their use as medicaments
|
DE10306250A1
(de)
|
2003-02-14 |
2004-09-09 |
Aventis Pharma Deutschland Gmbh |
Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
DE10308355A1
(de)
|
2003-02-27 |
2004-12-23 |
Aventis Pharma Deutschland Gmbh |
Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
|
DE10308353A1
(de)
|
2003-02-27 |
2004-12-02 |
Aventis Pharma Deutschland Gmbh |
Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
US7148246B2
(en)
|
2003-02-27 |
2006-12-12 |
Sanofi-Aventis Deutschland Gmbh |
Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
|
DE10308352A1
(de)
|
2003-02-27 |
2004-09-09 |
Aventis Pharma Deutschland Gmbh |
Arylcycloalkylderivate mit verzweigten Seitenketten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
|
DE10308351A1
(de)
|
2003-02-27 |
2004-11-25 |
Aventis Pharma Deutschland Gmbh |
1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
JP4548335B2
(ja)
|
2003-03-07 |
2010-09-22 |
味の素株式会社 |
腸管細胞のインスリン産生細胞への変換誘導剤、及び糖尿病治療剤
|
US7501440B2
(en)
|
2003-03-07 |
2009-03-10 |
Sanofi-Aventis Deutschland Gmbh |
Substituted benzoylureidopyridylpiperidine-and-pyrrolidinecarboxylic acid derivatives, processes for preparing them and their use
|
JP2006520818A
(ja)
|
2003-03-19 |
2006-09-14 |
イーライ リリー アンド カンパニー |
ポリエチレングリコール結合glp−1化合物
|
US7847063B2
(en)
|
2003-03-28 |
2010-12-07 |
Sanwa Kagaku Kenkyusho Co., Ltd. |
GLP-1 derivative
|
DE10314610A1
(de)
|
2003-04-01 |
2004-11-04 |
Aventis Pharma Deutschland Gmbh |
Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung
|
ATE482747T1
(de)
|
2003-04-11 |
2010-10-15 |
High Point Pharmaceuticals Llc |
Neue amide derivate und deren pharmazeutische verwendungen
|
CA2523267C
(en)
|
2003-04-23 |
2013-09-03 |
Biovalve Technologies, Inc. |
Hydraulically actuated pump for long duration medicament administration
|
EP1633391B1
(en)
|
2003-06-03 |
2011-10-19 |
Novo Nordisk A/S |
Stabilized pharmaceutical peptide compositions
|
JP4936884B2
(ja)
|
2003-06-03 |
2012-05-23 |
ノボ・ノルデイスク・エー/エス |
安定化された薬学的ペプチド組成物
|
KR20060106812A
(ko)
|
2003-08-21 |
2006-10-12 |
노보 노르디스크 에이/에스 |
라세미화 아미노산을 포함하는 폴리펩티드의 분리
|
WO2005023291A2
(en)
*
|
2003-09-11 |
2005-03-17 |
Novo Nordisk A/S |
Use of glp1-agonists in the treatment of patients with type i diabetes
|
CN100444898C
(zh)
*
|
2003-09-19 |
2008-12-24 |
诺沃挪第克公司 |
治疗肽的清蛋白结合型衍生物
|
ES2373660T3
(es)
*
|
2003-11-13 |
2012-02-07 |
Novo Nordisk A/S |
Composición farmacéutica que comprende un análogo insulinotrópico de glp-1 (7-37), insulina asp(b28) y un tensioactivo.
|
US20060287221A1
(en)
|
2003-11-13 |
2006-12-21 |
Novo Nordisk A/S |
Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
|
CN102784386A
(zh)
|
2003-11-20 |
2012-11-21 |
诺沃挪第克公司 |
对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
|
ATE498404T1
(de)
|
2003-12-09 |
2011-03-15 |
Novo Nordisk As |
Regulierung der nahrungspräferenz mit glp-1- agonisten
|
JP2007514752A
(ja)
|
2003-12-16 |
2007-06-07 |
ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス |
Glp−1医薬組成物
|
WO2005058955A1
(en)
*
|
2003-12-16 |
2005-06-30 |
Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. |
Analogues of glp-1
|
BRPI0417717A
(pt)
|
2003-12-18 |
2007-04-03 |
Novo Nordisk As |
composto, composição farmacêutica, e, uso de um composto
|
US20060286129A1
(en)
|
2003-12-19 |
2006-12-21 |
Emisphere Technologies, Inc. |
Oral GLP-1 formulations
|
CA2551324C
(en)
|
2004-01-06 |
2012-11-27 |
Novo Nordisk A/S |
Heteroaryl-ureas and their use as glucokinase activators
|
AU2005203925A1
(en)
*
|
2004-01-08 |
2005-07-21 |
Theratechnologies Inc. |
Glucagon-Like Peptide-1 analogs with long duration of action
|
CA2552043A1
(en)
|
2004-01-21 |
2005-08-04 |
Novo Nordisk A/S |
Transglutaminase mediated conjugation of peptides
|
US7241787B2
(en)
|
2004-01-25 |
2007-07-10 |
Sanofi-Aventis Deutschland Gmbh |
Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments
|
US7498341B2
(en)
|
2004-01-31 |
2009-03-03 |
Sanofi Aventis Deutschland Gmbh |
Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
|
US7470706B2
(en)
|
2004-01-31 |
2008-12-30 |
Sanofi-Aventis Deutschland Gmbh |
Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
|
US7402674B2
(en)
|
2004-01-31 |
2008-07-22 |
Sanofi-Aventis Deutschland Gmbh, |
7-Phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
|
DE102004005172A1
(de)
|
2004-02-02 |
2005-08-18 |
Aventis Pharma Deutschland Gmbh |
Indazolderivate als Inhibitoren der Hormon Sensitiven Lipase
|
KR100564618B1
(ko)
|
2004-03-11 |
2006-03-28 |
삼성전자주식회사 |
디스크 드라이브의 층간 탐색 방법
|
GT200500063A
(es)
|
2004-04-01 |
2005-10-14 |
|
Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias
|
DE602004004631D1
(de)
|
2004-04-01 |
2007-03-22 |
Sanofi Aventis Deutschland |
Oxadiazolone, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Pharmazeutika
|
EP1604988A1
(en)
|
2004-05-18 |
2005-12-14 |
Sanofi-Aventis Deutschland GmbH |
Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
|
WO2005120492A1
(en)
|
2004-06-11 |
2005-12-22 |
Novo Nordisk A/S |
Counteracting drug-induced obesity using glp-1 agonists
|
WO2006014425A1
(en)
|
2004-07-02 |
2006-02-09 |
Biovalve Technologies, Inc. |
Methods and devices for delivering glp-1 and uses thereof
|
PL1789434T3
(pl)
|
2004-08-31 |
2014-07-31 |
Novo Nordisk As |
Zastosowanie tris(hydroksymetylo)aminometanu do stabilizacji peptydów, polipeptydów i białek
|
WO2006028970A1
(en)
|
2004-09-02 |
2006-03-16 |
Cengent Therapeutics, Inc. |
Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases
|
US8030273B2
(en)
|
2004-10-07 |
2011-10-04 |
Novo Nordisk A/S |
Protracted exendin-4 compounds
|
JP2008515856A
(ja)
|
2004-10-07 |
2008-05-15 |
ノボ ノルディスク アクティーゼルスカブ |
遅延性glp−1化合物
|
AU2005303777B2
(en)
*
|
2004-11-12 |
2010-12-16 |
Novo Nordisk A/S |
Stable formulations of insulinotropic peptides
|
GB0426146D0
(en)
|
2004-11-29 |
2004-12-29 |
Bioxell Spa |
Therapeutic peptides and method
|
CA2590720A1
(en)
|
2004-12-03 |
2006-06-08 |
Lone Jeppesen |
Heteroaromatic glucokinase activators
|
TWI376234B
(en)
|
2005-02-01 |
2012-11-11 |
Msd Oss Bv |
Conjugates of a polypeptide and an oligosaccharide
|
ES2438145T3
(es)
|
2005-02-02 |
2014-01-16 |
Novo Nordisk A/S |
Nuevos derivados de insulina
|
WO2006082205A1
(en)
|
2005-02-02 |
2006-08-10 |
Novo Nordisk A/S |
Insulin derivatives
|
TWI362392B
(en)
|
2005-03-18 |
2012-04-21 |
Novo Nordisk As |
Acylated glp-1 compounds
|
CA2596926A1
(en)
|
2005-03-18 |
2006-09-21 |
Novo Nordisk A/S |
Extended glp-1 compounds
|
US7905868B2
(en)
|
2006-08-23 |
2011-03-15 |
Medtronic Minimed, Inc. |
Infusion medium delivery device and method with drive device for driving plunger in reservoir
|
US9233203B2
(en)
|
2005-05-06 |
2016-01-12 |
Medtronic Minimed, Inc. |
Medical needles for damping motion
|
US8137314B2
(en)
|
2006-08-23 |
2012-03-20 |
Medtronic Minimed, Inc. |
Infusion medium delivery device and method with compressible or curved reservoir or conduit
|
US20080097291A1
(en)
|
2006-08-23 |
2008-04-24 |
Hanson Ian B |
Infusion pumps and methods and delivery devices and methods with same
|
US8840586B2
(en)
|
2006-08-23 |
2014-09-23 |
Medtronic Minimed, Inc. |
Systems and methods allowing for reservoir filling and infusion medium delivery
|
US8277415B2
(en)
|
2006-08-23 |
2012-10-02 |
Medtronic Minimed, Inc. |
Infusion medium delivery device and method with drive device for driving plunger in reservoir
|
US8512288B2
(en)
|
2006-08-23 |
2013-08-20 |
Medtronic Minimed, Inc. |
Infusion medium delivery device and method with drive device for driving plunger in reservoir
|
US20090227493A1
(en)
*
|
2005-05-27 |
2009-09-10 |
Daiichi Sankyo Company, Limited |
Combined drug for treating diabetes
|
DE102005026762A1
(de)
|
2005-06-09 |
2006-12-21 |
Sanofi-Aventis Deutschland Gmbh |
Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen
|
ATE529404T1
(de)
|
2005-06-30 |
2011-11-15 |
High Point Pharmaceuticals Llc |
Phenoxyessigsäuren als ppar-delta-aktivatoren
|
MX2007015675A
(es)
|
2005-07-04 |
2008-02-20 |
Novo Nordisk As |
Antagonistas del receptor de histamina h3.
|
JP4960355B2
(ja)
|
2005-07-14 |
2012-06-27 |
ノボ・ノルデイスク・エー/エス |
ウレア型グルコキナーゼ活性化剤
|
EP1910317B1
(en)
|
2005-07-20 |
2013-07-03 |
Eli Lilly And Company |
1-amino linked compounds
|
DK1767545T3
(da)
*
|
2005-09-22 |
2010-03-15 |
Biocompatibles Uk Ltd |
GLP-1 (Glucagon-lignende peptid-1)-fusionspolypeptider med forøget peptidaseresistens
|
WO2007123581A1
(en)
|
2005-11-17 |
2007-11-01 |
Eli Lilly And Company |
Glucagon receptor antagonists, preparation and therapeutic uses
|
ES2390286T3
(es)
|
2005-12-16 |
2012-11-08 |
Nektar Therapeutics |
Conjugados poliméricos de GLP-1
|
EA015717B1
(ru)
|
2005-12-22 |
2011-10-31 |
ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи |
Феноксиуксусные кислоты в качестве активаторов ppar дельта
|
WO2007084460A2
(en)
|
2006-01-18 |
2007-07-26 |
Qps, Llc |
Pharmaceutical compositions with enhanced stability
|
US11497846B2
(en)
|
2006-02-09 |
2022-11-15 |
Deka Products Limited Partnership |
Patch-sized fluid delivery systems and methods
|
US11364335B2
(en)
|
2006-02-09 |
2022-06-21 |
Deka Products Limited Partnership |
Apparatus, system and method for fluid delivery
|
US11478623B2
(en)
|
2006-02-09 |
2022-10-25 |
Deka Products Limited Partnership |
Infusion pump assembly
|
US12070574B2
(en)
|
2006-02-09 |
2024-08-27 |
Deka Products Limited Partnership |
Apparatus, systems and methods for an infusion pump assembly
|
US11027058B2
(en)
|
2006-02-09 |
2021-06-08 |
Deka Products Limited Partnership |
Infusion pump assembly
|
US10010669B2
(en)
|
2006-02-09 |
2018-07-03 |
Deka Products Limited Partnership |
Systems and methods for fluid delivery
|
EP1993633B1
(en)
|
2006-02-09 |
2016-11-09 |
Deka Products Limited Partnership |
Pumping fluid delivery systems and methods using force application assembly
|
US9492606B2
(en)
|
2006-02-09 |
2016-11-15 |
Deka Products Limited Partnership |
Apparatus, system and methods for an infusion pump assembly
|
PL2383271T3
(pl)
|
2006-03-13 |
2013-12-31 |
Kyorin Seiyaku Kk |
Aminochinolony jako inhibitory GSK-3
|
WO2007104786A1
(en)
|
2006-03-15 |
2007-09-20 |
Novo Nordisk A/S |
Mixtures of amylin and insulin
|
NZ570524A
(en)
|
2006-03-28 |
2011-08-26 |
High Point Pharmaceuticals Llc |
Benzothiazoles having histamine H3 receptor activity
|
WO2007115039A2
(en)
|
2006-03-30 |
2007-10-11 |
Valeritas, Llc |
Multi-cartridge fluid delivery device
|
ES2378574T3
(es)
|
2006-04-24 |
2012-04-16 |
Eli Lilly & Company |
Pirrolidinonas ciclohexilo substituidas como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1
|
ATE444741T1
(de)
|
2006-05-10 |
2009-10-15 |
Biocompatibles Uk Ltd |
Glp-1 peptide enthaltende kugelförmige mikrokapseln, deren produktion und deren verwendung
|
CN101460487A
(zh)
|
2006-05-29 |
2009-06-17 |
高点制药有限责任公司 |
3-(1,3-苯并间二氧杂环戊烯- 5-基)-6-(4-环丙基哌嗪-1-基)-哒嗪、其盐和溶剂合物及其作为组胺h3受体拮抗剂的用途
|
DE102006028862A1
(de)
|
2006-06-23 |
2007-12-27 |
Merck Patent Gmbh |
3-Amino-imidazo[1,2-a]pyridinderivate
|
WO2008008363A1
(en)
|
2006-07-11 |
2008-01-17 |
Qps, Llc |
Pharmaceutical compositions for sustained release delivery of peptides
|
BRPI0714334A2
(pt)
|
2006-07-18 |
2013-05-14 |
Centocor Inc |
mimeticorpos de glp-1 humano aperfeiÇoados, composiÇÕes, mÉtodos e usos
|
BRPI0715160A2
(pt)
|
2006-08-08 |
2013-06-11 |
Sanofi Aventis |
imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
|
US7811262B2
(en)
|
2006-08-23 |
2010-10-12 |
Medtronic Minimed, Inc. |
Systems and methods allowing for reservoir filling and infusion medium delivery
|
US7794434B2
(en)
|
2006-08-23 |
2010-09-14 |
Medtronic Minimed, Inc. |
Systems and methods allowing for reservoir filling and infusion medium delivery
|
US7736338B2
(en)
|
2006-08-23 |
2010-06-15 |
Medtronic Minimed, Inc. |
Infusion medium delivery system, device and method with needle inserter and needle inserter device and method
|
US7828764B2
(en)
|
2006-08-23 |
2010-11-09 |
Medtronic Minimed, Inc. |
Systems and methods allowing for reservoir filling and infusion medium delivery
|
JP5570809B2
(ja)
|
2006-09-01 |
2014-08-13 |
ノボ ノルディスク ヘルス ケア アーゲー |
修飾タンパク質
|
US20100179131A1
(en)
|
2006-09-07 |
2010-07-15 |
Nycomed Gmbh |
Combination treatment for diabetes mellitus
|
WO2008059025A1
(en)
|
2006-11-15 |
2008-05-22 |
High Point Pharmaceuticals, Llc |
Novel 2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes
|
TWI428346B
(zh)
|
2006-12-13 |
2014-03-01 |
Imp Innovations Ltd |
新穎化合物及其等對進食行為影響
|
US8318778B2
(en)
|
2007-01-11 |
2012-11-27 |
Novo Nordisk A/S |
Urea glucokinase activators
|
DE102007002260A1
(de)
|
2007-01-16 |
2008-07-31 |
Sanofi-Aventis |
Verwendung von substituierten Pyranonsäurederivaten zur Herstellung von Medikamenten zur Behandlung des Metabolischen Syndroms
|
DE102007005045B4
(de)
|
2007-01-26 |
2008-12-18 |
Sanofi-Aventis |
Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
EP2121077A1
(en)
|
2007-02-09 |
2009-11-25 |
Deka Products Limited Partnership |
Automated insertion assembly
|
DE102007008420A1
(de)
|
2007-02-21 |
2008-08-28 |
Merck Patent Gmbh |
Benzimidazolderivate
|
EP1975176A1
(en)
*
|
2007-03-27 |
2008-10-01 |
Biocompatibles UK Limited |
Novel glp-1 fusion peptides, their production and use
|
US8434528B2
(en)
|
2007-04-30 |
2013-05-07 |
Medtronic Minimed, Inc. |
Systems and methods for reservoir filling
|
DK2146760T3
(en)
|
2007-04-30 |
2019-01-28 |
Medtronic Minimed Inc |
FILLING OF RESERVOIR, BUBBLE MANAGEMENT AND DELIVERY SYSTEMS FOR INFUSION MEDIA AND PROCEDURES
|
US7959715B2
(en)
|
2007-04-30 |
2011-06-14 |
Medtronic Minimed, Inc. |
Systems and methods allowing for reservoir air bubble management
|
US8597243B2
(en)
|
2007-04-30 |
2013-12-03 |
Medtronic Minimed, Inc. |
Systems and methods allowing for reservoir air bubble management
|
US8613725B2
(en)
|
2007-04-30 |
2013-12-24 |
Medtronic Minimed, Inc. |
Reservoir systems and methods
|
US7963954B2
(en)
|
2007-04-30 |
2011-06-21 |
Medtronic Minimed, Inc. |
Automated filling systems and methods
|
US8323250B2
(en)
|
2007-04-30 |
2012-12-04 |
Medtronic Minimed, Inc. |
Adhesive patch systems and methods
|
CN101742906A
(zh)
|
2007-06-04 |
2010-06-16 |
本古里安大学内盖夫研究发展局 |
三芳基化合物和包含它们的组合物
|
US20080319221A1
(en)
|
2007-06-22 |
2008-12-25 |
Bernd Junker |
Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids
|
EP2170945A1
(en)
|
2007-07-16 |
2010-04-07 |
Novo Nordisk A/S |
Protease stabilized, pegylated insulin analogues
|
JP2009019027A
(ja)
*
|
2007-07-16 |
2009-01-29 |
Hanmi Pharmaceutical Co Ltd |
アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
|
EP2025674A1
(de)
|
2007-08-15 |
2009-02-18 |
sanofi-aventis |
Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
CN101842386A
(zh)
|
2007-09-05 |
2010-09-22 |
诺沃-诺迪斯克有限公司 |
截短的glp-1衍生物和它们的治疗用途
|
JP5606314B2
(ja)
|
2007-09-05 |
2014-10-15 |
ノボ・ノルデイスク・エー/エス |
A−b−c−d−で誘導体化されたペプチドとその治療用途
|
CN101868476B
(zh)
|
2007-09-05 |
2015-02-25 |
诺沃-诺迪斯克有限公司 |
胰高血糖素样肽-1衍生物及其制药用途
|
AU2008299903B2
(en)
|
2007-09-11 |
2013-08-29 |
Kyorin Pharmaceutical Co., Ltd |
Cyanoaminoquinolones and tetrazoloaminoquinolones as GSK-3 inhibitors
|
US8476261B2
(en)
|
2007-09-12 |
2013-07-02 |
Kyorin Pharmaceutical Co., Ltd. |
Spirocyclic aminoquinolones as GSK-3 inhibitors
|
DE102007048716A1
(de)
|
2007-10-11 |
2009-04-23 |
Merck Patent Gmbh |
Imidazo[1,2-a]pyrimidinderivate
|
DE102007063671A1
(de)
|
2007-11-13 |
2009-06-25 |
Sanofi-Aventis Deutschland Gmbh |
Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
PL2209800T3
(pl)
|
2007-11-16 |
2013-12-31 |
Novo Nordisk As |
Stabilne kompozycje farmaceutyczne zawierające liraglutyd i degludec
|
US20100317057A1
(en)
|
2007-12-28 |
2010-12-16 |
Novo Nordisk A/S |
Semi-recombinant preparation of glp-1 analogues
|
US8881774B2
(en)
|
2007-12-31 |
2014-11-11 |
Deka Research & Development Corp. |
Apparatus, system and method for fluid delivery
|
US10080704B2
(en)
|
2007-12-31 |
2018-09-25 |
Deka Products Limited Partnership |
Apparatus, system and method for fluid delivery
|
US8900188B2
(en)
|
2007-12-31 |
2014-12-02 |
Deka Products Limited Partnership |
Split ring resonator antenna adapted for use in wirelessly controlled medical device
|
JP5634269B2
(ja)
|
2007-12-31 |
2014-12-03 |
デカ・プロダクツ・リミテッド・パートナーシップ |
注入ポンプアセンブリ
|
WO2009088956A2
(en)
|
2007-12-31 |
2009-07-16 |
Deka Products Limited Partnership |
Infusion pump assembly
|
US9456955B2
(en)
|
2007-12-31 |
2016-10-04 |
Deka Products Limited Partnership |
Apparatus, system and method for fluid delivery
|
US10188787B2
(en)
|
2007-12-31 |
2019-01-29 |
Deka Products Limited Partnership |
Apparatus, system and method for fluid delivery
|
BRPI0907371A2
(pt)
|
2008-01-09 |
2015-11-24 |
Sanofi Aventis Deutschland |
derivados de insulina com um perfil de tempo-ação muito retardado
|
DE102008025008A1
(de)
|
2008-05-24 |
2009-11-26 |
Sanofi-Aventis Deutschland Gmbh |
Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
|
NZ586589A
(en)
|
2008-01-09 |
2012-04-27 |
Sanofi Aventis Deutschland |
Novel insulin analogues having an extremely delayed time-action profile
|
DE102008025007A1
(de)
|
2008-05-24 |
2009-11-26 |
Sanofi-Aventis Deutschland Gmbh |
Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
|
DE102008003566A1
(de)
|
2008-01-09 |
2009-07-16 |
Sanofi-Aventis Deutschland Gmbh |
Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
|
DE102008003568A1
(de)
|
2008-01-09 |
2009-07-16 |
Sanofi-Aventis Deutschland Gmbh |
Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
|
WO2009109927A2
(en)
*
|
2008-03-05 |
2009-09-11 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Glp-1 receptor agonists and related active pharmaceutical ingredients for treatment of cancer
|
EP2910571B1
(en)
|
2008-03-18 |
2016-10-05 |
Novo Nordisk A/S |
Protease stabilized, acylated insulin analogues
|
DE102008017590A1
(de)
|
2008-04-07 |
2009-10-08 |
Merck Patent Gmbh |
Glucopyranosidderivate
|
CN101555214B
(zh)
|
2008-04-08 |
2012-07-11 |
北京嘉事联博医药科技有限公司 |
苯基环丁基酰胺衍生物及其光学异构体、制备方法和用途
|
EP4074327A1
(en)
|
2008-06-27 |
2022-10-19 |
Duke University |
Therapeutic agents comprising elastin-like peptides
|
WO2010003624A2
(en)
|
2008-07-09 |
2010-01-14 |
Sanofi-Aventis |
Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
|
WO2010015668A1
(en)
|
2008-08-06 |
2010-02-11 |
Novo Nordisk A/S |
Conjugated proteins with prolonged in vivo efficacy
|
ES2561208T3
(es)
|
2008-09-12 |
2016-02-25 |
Novo Nordisk A/S |
Método de acilación de un péptido o una proteína
|
DE102009038210A1
(de)
|
2009-08-20 |
2011-03-03 |
Sanofi-Aventis Deutschland Gmbh |
Kombination von einem Insulin und einem GLP-1-Agonisten
|
DK2349324T3
(en)
|
2008-10-17 |
2017-12-11 |
Sanofi Aventis Deutschland |
COMBINATION OF AN INSULIN AND A GLP-1 AGONIST
|
DE102008053048A1
(de)
|
2008-10-24 |
2010-04-29 |
Sanofi-Aventis Deutschland Gmbh |
Kombination von einem Insulin und einem GLP-1-Agonisten
|
DE102008051834A1
(de)
|
2008-10-17 |
2010-04-22 |
Sanofi-Aventis Deutschland Gmbh |
Kombination von einem Insulin und einem GLP-1-Agonisten
|
ES2614427T3
(es)
|
2008-11-07 |
2017-05-31 |
The General Hospital Corporation |
Fragmentos C-terminales de péptido glucagonoide 1 (GLP-1)
|
IT1392655B1
(it)
|
2008-11-20 |
2012-03-16 |
Bio Ker S R L |
Site-specific monoconjugated insulinotropic glp-1 peptides.
|
CN102223797A
(zh)
|
2008-11-21 |
2011-10-19 |
高点制药有限责任公司 |
金刚烷基苯甲酰胺化合物
|
MX2011005963A
(es)
|
2008-12-05 |
2011-09-01 |
Angiochem Inc |
Conjugados de neurotensina o analogos de neurotensina y sus usos.
|
WO2010068601A1
(en)
|
2008-12-08 |
2010-06-17 |
Sanofi-Aventis |
A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
|
DK2370462T3
(da)
|
2008-12-15 |
2014-09-08 |
Zealand Pharma As |
Glucagon-analoger
|
JP5635530B2
(ja)
|
2008-12-15 |
2014-12-03 |
ジーランド ファーマ アクティーゼルスカブ |
グルカゴン類似体
|
DK2370461T3
(da)
|
2008-12-15 |
2013-12-16 |
Zealand Pharma As |
Glucagonanaloger
|
CN102282167B
(zh)
|
2008-12-15 |
2014-08-13 |
西兰制药公司 |
胰高血糖素类似物
|
AU2010207725B2
(en)
|
2009-01-22 |
2015-06-11 |
Novo Nordisk Health Care Ag |
Stable growth hormone compounds
|
AU2010207721B2
(en)
|
2009-01-23 |
2015-03-26 |
Novo Nordisk A/S |
FGF21 derivatives with albumin binder A-B-C-D-E- and their use
|
CN101824087A
(zh)
*
|
2009-03-05 |
2010-09-08 |
连云港恒邦医药科技有限公司 |
胰高血糖素样肽-2类似物及其制备方法和用途
|
CN102421784B
(zh)
|
2009-03-11 |
2015-09-30 |
杏林制药株式会社 |
作为gsk-3抑制剂的7-环烷基氨基喹诺酮
|
BRPI1009619B8
(pt)
|
2009-06-05 |
2021-05-25 |
Veroscience Llc |
forma de dosagem farmacêutica
|
AU2014265118B2
(en)
*
|
2009-06-05 |
2016-11-17 |
Veroscience Llc |
Combination of dopamine agonists plus first phase insulin secretagouges for the treatment of metabolic disorders
|
US9352025B2
(en)
|
2009-06-05 |
2016-05-31 |
Veroscience Llc |
Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
|
JP2012529463A
(ja)
*
|
2009-06-11 |
2012-11-22 |
ノヴォ ノルディスク アー/エス |
2型糖尿病を治療するための、glp−1とfgf21との組合せ
|
US9156901B2
(en)
|
2009-07-13 |
2015-10-13 |
Ditte Riber |
Acylated glucagon analogues
|
US8614182B2
(en)
|
2009-07-30 |
2013-12-24 |
Jiangsu Hansoh Pharmaceuticals Co., Ltd. |
GLP-1 analogues and their pharmaceutical salts and uses
|
CN101987868B
(zh)
|
2009-07-30 |
2013-09-04 |
江苏豪森医药集团有限公司 |
Glp-1类似物的衍生物或其可药用盐和用途
|
US8841249B2
(en)
|
2009-08-06 |
2014-09-23 |
Novo Nordisk A/S |
Growth hormones with prolonged in-vivo efficacy
|
EP2470552B1
(en)
|
2009-08-26 |
2013-11-13 |
Sanofi |
Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
|
EP2482823A2
(en)
|
2009-10-02 |
2012-08-08 |
Sanofi |
Use of compounds with sglt-1/sglt-2 inhibitor activity for producing medicaments for treatment of bone diseases
|
US20120264685A1
(en)
|
2009-10-22 |
2012-10-18 |
Rajesh Bahekar |
Short chain peptidomimetics based orally active glp 1 agonist and glucagon receptor antagonist
|
JP5973918B2
(ja)
|
2009-11-13 |
2016-08-23 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
Glp−1アゴニスト及びメチオニンを含む薬学的組成物
|
KR101836070B1
(ko)
|
2009-11-13 |
2018-03-09 |
사노피-아벤티스 도이칠란트 게엠베하 |
Glp-1 작용제, 인슐린 및 메티오닌을 포함하는 약제학적 조성물
|
PL2513140T3
(pl)
*
|
2009-12-16 |
2016-04-29 |
Novo Nordisk As |
Podwójnie acylowane pochodne glp-1
|
AU2011208625C1
(en)
|
2010-01-22 |
2022-08-18 |
Novo Nordisk Health Care Ag |
Growth hormones with prolonged in-vivo efficacy
|
CA2787895A1
(en)
|
2010-01-22 |
2011-07-28 |
Novo Nordisk Health Care Ag |
Stable growth hormone compounds
|
WO2011091265A1
(en)
|
2010-01-22 |
2011-07-28 |
Deka Products Limited Partnership |
Method and system for shape-memory alloy wire control
|
US20130012432A1
(en)
|
2010-02-26 |
2013-01-10 |
Novo Nordisk A/S |
Peptides for Treatment of Obesity
|
BR112012021231A2
(pt)
|
2010-02-26 |
2015-09-08 |
Basf Plant Science Co Gmbh |
método para acentuar o rendimento em plantas, planta, construto, uso de um construto, método para a produção de uma planta transgênica, partes coletáveis de uma planta, produtos derivados de uma planta, uso de um ácido nucleíco e método para a produção de um produto
|
JP5992836B2
(ja)
*
|
2010-03-01 |
2016-09-14 |
ノヴォ ノルディスク アー/エス |
ペプチドを精製するための分取rp−hplc法
|
WO2011107494A1
(de)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
JP6054861B2
(ja)
|
2010-03-26 |
2016-12-27 |
ノヴォ ノルディスク アー/エス |
新規のグルカゴン類似体
|
WO2011123943A1
(en)
|
2010-04-09 |
2011-10-13 |
Mount Sinai Hospital |
Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist
|
DE102010015123A1
(de)
|
2010-04-16 |
2011-10-20 |
Sanofi-Aventis Deutschland Gmbh |
Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
CA2797133C
(en)
|
2010-04-27 |
2019-08-06 |
Zealand Pharma A/S |
Peptide conjugates of glp-1 receptor agonists and gastrin and their use
|
WO2011136361A1
(ja)
|
2010-04-30 |
2011-11-03 |
株式会社 三和化学研究所 |
生理活性物質等の生体内安定性向上のためのペプチド及び生体内安定性が向上した生理活性物質
|
EP2582709B1
(de)
|
2010-06-18 |
2018-01-24 |
Sanofi |
Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
|
US8530413B2
(en)
|
2010-06-21 |
2013-09-10 |
Sanofi |
Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
|
UY33462A
(es)
|
2010-06-23 |
2012-01-31 |
Zealand Pharma As |
Analogos de glucagon
|
PE20130338A1
(es)
|
2010-06-24 |
2013-03-16 |
Zealand Pharma As |
Analogos del glucagon
|
TW201215388A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Sa |
(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
|
TW201215387A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Aventis |
Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
|
TW201221505A
(en)
|
2010-07-05 |
2012-06-01 |
Sanofi Sa |
Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
|
PT2611458T
(pt)
|
2010-08-30 |
2016-12-16 |
Sanofi Aventis Deutschland |
Utilização de ave0010 para o fabrico de um medicamento para o tratamento da diabetes mellitus tipo 2
|
WO2012061466A2
(en)
|
2010-11-02 |
2012-05-10 |
The General Hospital Corporation |
Methods for treating steatotic disease
|
US9708383B2
(en)
|
2010-11-09 |
2017-07-18 |
Novo Nordisk A/S |
Double-acylated GLP-1 derivatives
|
RS56998B1
(sr)
|
2010-12-16 |
2018-05-31 |
Novo Nordisk As |
Čvrste kompozicije koje sadrže agonist glp-1 i so n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline
|
EP2665470A1
(en)
|
2011-01-19 |
2013-11-27 |
Novo Nordisk A/S |
Glp-1 particles and compositions
|
WO2012098187A1
(en)
|
2011-01-19 |
2012-07-26 |
Novo Nordisk A/S |
Glp-1 compositions
|
AU2012208349A1
(en)
|
2011-01-20 |
2013-07-18 |
Zealand Pharma A/S |
Combination of acylated glucagon analogues with insulin analogues
|
US10130684B2
(en)
|
2011-02-03 |
2018-11-20 |
Pharmedica Ltd. |
Oral dissolving films for insulin administration, for treating diabetes
|
WO2012120052A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
US8871758B2
(en)
|
2011-03-08 |
2014-10-28 |
Sanofi |
Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
|
WO2012120055A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
US8828995B2
(en)
|
2011-03-08 |
2014-09-09 |
Sanofi |
Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
|
EP2683702B1
(de)
|
2011-03-08 |
2014-12-24 |
Sanofi |
Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
EP2683698B1
(de)
|
2011-03-08 |
2017-10-04 |
Sanofi |
Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
EP2683701B1
(de)
|
2011-03-08 |
2014-12-24 |
Sanofi |
Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
US8828994B2
(en)
|
2011-03-08 |
2014-09-09 |
Sanofi |
Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
|
WO2012120057A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
CN103596583B
(zh)
|
2011-03-28 |
2016-07-27 |
诺沃—诺迪斯克有限公司 |
新型胰高血糖素类似物
|
MX355361B
(es)
*
|
2011-04-12 |
2018-04-17 |
Novo Nordisk As |
Derivados de peptido 1 tipo glucagon (glp-1) doblemente acilados.
|
WO2012150503A2
(en)
|
2011-05-03 |
2012-11-08 |
Zealand Pharma A/S |
Glu-glp-1 dual agonist signaling-selective compounds
|
EP2707713A2
(en)
|
2011-05-10 |
2014-03-19 |
Zealand Pharma A/S |
Glu-glp-1 dual agonist signaling-selective compounds
|
US9821032B2
(en)
|
2011-05-13 |
2017-11-21 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
|
WO2013006692A2
(en)
|
2011-07-06 |
2013-01-10 |
The General Hospital Corporation |
Methods of treatment using a pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1)
|
CN108079281A
(zh)
|
2011-08-29 |
2018-05-29 |
赛诺菲-安万特德国有限公司 |
用于2型糖尿病患者中的血糖控制的药物组合
|
AR087744A1
(es)
|
2011-09-01 |
2014-04-16 |
Sanofi Aventis Deutschland |
Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
|
CN103189389B
(zh)
*
|
2011-09-03 |
2017-08-11 |
深圳市健元医药科技有限公司 |
新的glp‑ⅰ类似物及其制备方法和用途
|
US9758560B2
(en)
|
2011-09-06 |
2017-09-12 |
Novo Nordisk A/S |
GLP-1 derivatives
|
EP2567959B1
(en)
|
2011-09-12 |
2014-04-16 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
WO2013037390A1
(en)
|
2011-09-12 |
2013-03-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
JP6352806B2
(ja)
|
2011-09-23 |
2018-07-04 |
ノヴォ ノルディスク アー/エス |
新規のグルカゴン類似体
|
US9458214B2
(en)
|
2011-09-26 |
2016-10-04 |
Novartis Ag |
Dual function fibroblast growth factor 21 proteins
|
WO2013045413A1
(en)
|
2011-09-27 |
2013-04-04 |
Sanofi |
6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
ES2562651T3
(es)
|
2011-10-04 |
2016-03-07 |
Sanofi-Aventis Deutschland Gmbh |
Lixisenatida para el uso en el tratamiento de la estenosis o/y la obstrucción del sistema de conductos pancreáticos
|
EP2763691A1
(en)
|
2011-10-04 |
2014-08-13 |
Sanofi-Aventis Deutschland GmbH |
Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the biliary tract
|
MX2014005351A
(es)
|
2011-11-03 |
2014-05-28 |
Zealand Pharma As |
Conjugados de gastrina peptidicos de agonistas de receptor glp-1.
|
US20150038417A1
(en)
|
2011-12-09 |
2015-02-05 |
Novo Nordisk A/S |
GLP-1 Agonists
|
WO2013098191A1
(en)
|
2011-12-29 |
2013-07-04 |
Novo Nordisk A/S |
Dipeptide comprising a non-proteogenic amino acid
|
EP3196214B1
(en)
|
2012-02-15 |
2019-07-31 |
Novo Nordisk A/S |
Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (trem-1)
|
EP2814842B1
(en)
|
2012-02-15 |
2018-08-22 |
Novo Nordisk A/S |
Antibodies that bind peptidoglycan recognition protein 1
|
US9550830B2
(en)
|
2012-02-15 |
2017-01-24 |
Novo Nordisk A/S |
Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
|
WO2013134519A2
(en)
|
2012-03-07 |
2013-09-12 |
Deka Products Limited Partnership |
Apparatus, system and method for fluid delivery
|
SI2827845T1
(sl)
|
2012-03-22 |
2019-04-30 |
Novo Nordisk A/S |
Sestavki, ki obsegajo dostavno sredstvo in njihova priprava
|
RU2641198C3
(ru)
|
2012-03-22 |
2021-12-10 |
Ново Нордиск А/С |
Композиции glp-1 пептидов и их получение
|
SG11201407137PA
(en)
|
2012-05-03 |
2014-11-27 |
Zealand Pharma As |
Gip-glp-1 dual agonist compounds and methods
|
CA2872315A1
(en)
|
2012-05-03 |
2013-11-07 |
Zealand Pharma A/S |
Glucagon-like-peptide-2 (glp-2) analogues
|
US11274135B2
(en)
*
|
2012-05-08 |
2022-03-15 |
Novo Nordisk A/S |
Double-acylated GLP-1 derivatives
|
CN104519902B
(zh)
|
2012-05-08 |
2017-10-27 |
诺和诺德股份有限公司 |
双酰化glp‑1衍生物
|
EP2664374A1
(en)
*
|
2012-05-15 |
2013-11-20 |
F. Hoffmann-La Roche AG |
Lysin-glutamic acid dipeptide derivatives
|
ES2871328T3
(es)
|
2012-06-20 |
2021-10-28 |
Novo Nordisk As |
Formulación de comprimido que comprende un péptido y un agente de suministro
|
BR112014032938A2
(pt)
|
2012-07-01 |
2017-08-01 |
Novo Nordisk As |
uso de peptídeos de glp-1 de longa ação
|
EP2873422A4
(en)
|
2012-07-10 |
2015-12-30 |
Takeda Pharmaceutical |
PHARMACEUTICAL PREPARATION FOR INJECTION
|
MX356957B
(es)
|
2012-07-23 |
2018-06-20 |
Zealand Pharma As |
Analogos del glucagon.
|
FR2994848B1
(fr)
|
2012-08-30 |
2014-08-22 |
Univ Paris Curie |
Traitement de l'arthrose par les hormones incretines ou leurs analogues
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
UA116217C2
(uk)
|
2012-10-09 |
2018-02-26 |
Санофі |
Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
|
CN104717972A
(zh)
|
2012-10-17 |
2015-06-17 |
诺和诺德A/S(股份有限公司) |
用于口服肽递送的脂肪酸酰化氨基酸
|
CN105142621A
(zh)
|
2012-10-24 |
2015-12-09 |
国家健康科学研究所 |
用于预防或治疗糖尿病和促进β-细胞存活的TPL2激酶抑制剂
|
US9867869B2
(en)
|
2012-12-12 |
2018-01-16 |
Massachusetts Institute Of Technology |
Insulin derivatives for diabetes treatment
|
AR094180A1
(es)
|
2012-12-21 |
2015-07-15 |
Sanofi Sa |
Derivados de exendina-4
|
CN103059127B
(zh)
*
|
2013-01-07 |
2014-12-17 |
天津嘉宏科技有限公司 |
Glp-1类似物及其制备方法与应用
|
US9707273B2
(en)
|
2013-03-01 |
2017-07-18 |
Fundació Hospital Universitari Vall D'hebron—Institut De Recerca |
Peptides for use in the topical treatment of retinal neurodegenerative diseases, in particular in early stages of diabetic retinopathy and other retinal diseases in which neurodegeneration plays an essential role
|
PT2968443T
(pt)
|
2013-03-15 |
2021-12-28 |
Protagonist Therapeutics Inc |
Análogos de hepcidina e seus usos
|
US11045523B2
(en)
|
2013-04-05 |
2021-06-29 |
Novo Nordisk Healthcare Ag |
Formulation of growth hormone albumin-binder conjugate
|
CN105307672B
(zh)
|
2013-04-18 |
2021-01-05 |
诺和诺德股份有限公司 |
用于医学用途的稳定、延长的glp-1/胰高血糖素受体共激动剂
|
US9617020B2
(en)
|
2013-07-03 |
2017-04-11 |
Deka Products Limited Partnership |
Apparatus, system and method for fluid delivery
|
US10266577B2
(en)
|
2013-08-15 |
2019-04-23 |
Novo Nordisk A/S |
GLP-1 derivatives, and uses thereof
|
GB201315335D0
(en)
|
2013-08-29 |
2013-10-09 |
Of Singapore |
Amino diacids containing peptide modifiers
|
US9988429B2
(en)
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
MX368436B
(es)
|
2013-10-17 |
2019-10-03 |
Zealand Pharma As |
Analogos de glucagon acilados.
|
JP6657101B2
(ja)
|
2013-11-05 |
2020-03-04 |
ベン グリオン ユニバーシティ オブ ザ ネガフ リサーチ アンド ディベロップメント オーソリティ |
糖尿病及びそれから生じる疾患合併症の治療のための化合物
|
WO2015067716A1
(en)
|
2013-11-06 |
2015-05-14 |
Zealand Pharma A/S |
Glucagon-glp-1-gip triple agonist compounds
|
EP3065767B1
(en)
|
2013-11-06 |
2020-12-30 |
Zealand Pharma A/S |
Gip-glp-1 dual agonist compounds and methods
|
EP3080149A1
(en)
|
2013-12-13 |
2016-10-19 |
Sanofi |
Dual glp-1/glucagon receptor agonists
|
WO2015086729A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Dual glp-1/gip receptor agonists
|
EP3080152A1
(en)
|
2013-12-13 |
2016-10-19 |
Sanofi |
Non-acylated exendin-4 peptide analogues
|
EP3080150B1
(en)
|
2013-12-13 |
2018-08-01 |
Sanofi |
Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
|
CN103884846B
(zh)
*
|
2014-03-06 |
2016-06-08 |
杭州九源基因工程有限公司 |
一种利拉鲁肽生物学活性的检测方法
|
TW201625669A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑
|
TW201625668A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物
|
ES2741507T3
(es)
*
|
2014-04-07 |
2020-02-11 |
Novo Nordisk As |
Compuestos de glp-1 acilados doblemente
|
TW201625670A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自exendin-4之雙重glp-1/升糖素受體促效劑
|
PL3139948T3
(pl)
|
2014-05-07 |
2020-08-10 |
Novo Nordisk A/S |
Leczenie cukrzycy z zastosowaniem glp-1 i anty-il-21
|
LT3143037T
(lt)
|
2014-05-16 |
2021-10-11 |
Protagonist Therapeutics, Inc. |
Alfa4beta7 integrino tioeterio peptidų antagonistaii
|
JP2017525656A
(ja)
|
2014-06-04 |
2017-09-07 |
ノヴォ ノルディスク アー/エス |
医療用のglp−1/グルカゴン受容体コアゴニスト
|
US9932381B2
(en)
|
2014-06-18 |
2018-04-03 |
Sanofi |
Exendin-4 derivatives as selective glucagon receptor agonists
|
CN104987383A
(zh)
*
|
2014-07-08 |
2015-10-21 |
四川百利药业有限责任公司 |
一种glp-1衍生物
|
GB2528436A
(en)
|
2014-07-15 |
2016-01-27 |
Lancaster Univ Business Entpr Ltd |
Treatment of neurological diseases
|
KR102465120B1
(ko)
|
2014-07-17 |
2022-11-10 |
노보 노르디스크 에이/에스 |
점도를 감소시키기 위한 trem-1 항체의 부위 지정 돌연변이유발
|
CN107206254B
(zh)
|
2014-07-17 |
2021-08-24 |
领导医疗有限公司 |
白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途
|
PL3189072T3
(pl)
|
2014-09-05 |
2019-04-30 |
Univ Copenhagen |
Analogi peptydowe gip
|
JP2017535527A
(ja)
|
2014-10-01 |
2017-11-30 |
プロタゴニスト セラピューティクス, インコーポレイテッド |
新規のα4β7ペプチド単量体及び二量体拮抗薬
|
EP3201217A4
(en)
|
2014-10-01 |
2018-07-18 |
Protagonist Therapeutics Inc. |
Novel cyclic monomer and dimer peptides having integrin antagonist activity
|
DK3006045T3
(en)
|
2014-10-07 |
2017-07-17 |
Cyprumed Gmbh |
Pharmaceutical formulations for oral administration of peptide or protein drugs
|
AU2015340586B2
(en)
|
2014-10-29 |
2020-04-30 |
Zealand Pharma A/S |
GIP agonist compounds and methods
|
US11572398B2
(en)
|
2014-11-27 |
2023-02-07 |
Novo Nordisk A/S |
GLP-1 derivatives and uses thereof
|
CN107206058A
(zh)
|
2014-12-12 |
2017-09-26 |
赛诺菲-安万特德国有限公司 |
甘精胰岛素/利西拉来固定比率配制剂
|
PL3236991T3
(pl)
|
2014-12-23 |
2019-12-31 |
Novo Nordisk A/S |
Pochodne fgf21 i ich zastosowania
|
TWI748945B
(zh)
|
2015-03-13 |
2021-12-11 |
德商賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患治療
|
PE20180497A1
(es)
|
2015-03-18 |
2018-03-09 |
Zealand Pharma As |
Analogos de amilina
|
TW201705975A
(zh)
|
2015-03-18 |
2017-02-16 |
賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患之治療
|
ES2805743T3
(es)
|
2015-03-24 |
2021-02-15 |
Inst Nat Sante Rech Med |
Método y composición farmacéutica para uso en el tratamiento de la diabetes
|
BR112017022009A2
(pt)
|
2015-04-16 |
2018-07-03 |
Zealand Pharma A/S |
?composto, método de produção e síntese do mesmo e seu uso, composição e conjunto terapêutico?
|
AR105319A1
(es)
|
2015-06-05 |
2017-09-27 |
Sanofi Sa |
Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
|
AR105284A1
(es)
|
2015-07-10 |
2017-09-20 |
Sanofi Sa |
Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
|
US10787490B2
(en)
|
2015-07-15 |
2020-09-29 |
Protaganist Therapeutics, Inc. |
Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
|
US10905744B2
(en)
|
2015-10-07 |
2021-02-02 |
Cyprumed Gmbh |
Pharmaceutical formulations for the oral delivery of peptide drugs
|
CA3009834A1
(en)
|
2015-12-30 |
2017-07-06 |
Protagonist Therapeutics, Inc. |
Analogues of hepcidin mimetics with improved in vivo half lives
|
EP3205660A1
(en)
|
2016-02-10 |
2017-08-16 |
Polypeptide Laboratories Holding (PPL) AB |
Method for preparation of peptides with pswang linker
|
WO2017127007A1
(en)
|
2016-01-20 |
2017-07-27 |
Poypeptide Laboratories Holding (Ppl) Ab |
METHOD FOR PREPARATION OF PEPTIDES WITH psWANG LINKER
|
EP3196206A1
(en)
|
2016-01-20 |
2017-07-26 |
Lonza Ltd |
Method for preparation of liraglutide
|
EP3205664A1
(en)
|
2016-02-11 |
2017-08-16 |
Polypeptide Laboratories Holding (PPL) AB |
Method for preparation of liraglutide using bal linker
|
CN108699126B
(zh)
|
2016-03-03 |
2022-12-06 |
诺和诺德股份有限公司 |
Glp-1衍生物及其用途
|
MA43684A
(fr)
|
2016-03-04 |
2018-11-28 |
Novo Nordisk As |
Liraglutide utilisé dans le traitement de maladies rénales
|
WO2017149109A1
(en)
|
2016-03-04 |
2017-09-08 |
Novo Nordisk A/S |
Liraglutide in diabetic foot ulcer
|
CN109641946A
(zh)
|
2016-03-23 |
2019-04-16 |
巴切姆股份公司 |
胰高血糖素样肽的制备方法
|
US10407468B2
(en)
|
2016-03-23 |
2019-09-10 |
Protagonist Therapeutics, Inc. |
Methods for synthesizing α4β7 peptide antagonists
|
EP3433268B1
(en)
|
2016-03-23 |
2021-07-28 |
Bachem Holding AG |
Purification of glucagon-like peptide 1 analogs
|
TWI784968B
(zh)
|
2016-09-09 |
2022-12-01 |
丹麥商西蘭製藥公司 |
澱粉素類似物
|
WO2018057977A1
(en)
|
2016-09-23 |
2018-03-29 |
Delpor, Inc. |
Stable compositions for incretin mimetic compounds
|
WO2018065634A1
(en)
|
2016-10-07 |
2018-04-12 |
Cyprumed Gmbh |
Pharmaceutical compositions for the nasal delivery of peptide or protein drugs
|
WO2018096164A1
(en)
|
2016-11-28 |
2018-05-31 |
Novo Nordisk A/S |
Insulin degludec for treating diabetes
|
WO2018096163A1
(en)
|
2016-11-28 |
2018-05-31 |
Novo Nordisk A/S |
Insulin degludec for improvement of glycaemic control and reduction of acute and long-term diabetes complications
|
WO2018096162A1
(en)
|
2016-11-28 |
2018-05-31 |
Novo Nordisk A/S |
Insulin degludec in cardiovascular conditions
|
WO2018104263A1
(en)
|
2016-12-06 |
2018-06-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of enhancing the potency of incretin-based drugs in subjects in need thereof
|
BR112019010624A2
(pt)
|
2016-12-09 |
2019-10-22 |
Zealand Pharma As |
agonistas duplos de glp-1/glp-2 acilados e composição
|
WO2018103868A1
(en)
|
2016-12-09 |
2018-06-14 |
Zealand Pharma A/S |
Acylated glp-1/glp-2 dual agonists
|
WO2018104558A1
(en)
|
2016-12-09 |
2018-06-14 |
Zealand Pharma A/S |
Acylated glp-1/glp-2 dual agonists
|
CN110099922A
(zh)
|
2016-12-09 |
2019-08-06 |
西兰制药公司 |
Glp-1/glp-2双重激动剂
|
GB201621987D0
(en)
|
2016-12-22 |
2017-02-08 |
Archer Virgil L See Archer Sheri A Arecor Ltd |
Novel composition
|
EP3596107A1
(en)
|
2017-03-15 |
2020-01-22 |
Novo Nordisk A/S |
Bicyclic compounds capable of binding to melanocortin 4 receptor
|
WO2018210919A1
(en)
|
2017-05-17 |
2018-11-22 |
Novo Nordisk A/S |
Glp-1 compositions and uses thereof
|
ES2972848T3
(es)
|
2017-05-31 |
2024-06-17 |
The Univ Of Copenhagen |
Análogos de péptido GIP de acción prolongada
|
KR102665710B1
(ko)
|
2017-08-24 |
2024-05-14 |
노보 노르디스크 에이/에스 |
Glp-1 조성물 및 그 용도
|
MA50233A
(fr)
|
2017-09-10 |
2020-07-22 |
Novo Nordisk As |
Mic-1 et glp-1 destinés à être utilisés dans le traitement de l'obésité
|
WO2019051494A1
(en)
|
2017-09-11 |
2019-03-14 |
Protagonist Therapeutics, Inc. |
OPIOID AGONIST PEPTIDES AND USES THEREOF
|
US20210261642A1
(en)
|
2017-12-19 |
2021-08-26 |
Novo Nordisk A/S |
Solubility of glp-1 peptide
|
IL275778B2
(en)
|
2018-02-02 |
2023-12-01 |
Novo Nordisk As |
Solid compounds that make up glp-1 agonist n-8-2-hydroxybenzoyl salt
|
EP3749345A4
(en)
|
2018-02-08 |
2022-04-06 |
Protagonist Therapeutics, Inc. |
CONJUGATED HEPCIDIN MIMETICS
|
US11965039B2
(en)
|
2018-02-27 |
2024-04-23 |
Zp Spv 3 K/S |
Compstatin analogues and their medical uses
|
KR20200139219A
(ko)
|
2018-04-02 |
2020-12-11 |
브리스톨-마이어스 스큅 컴퍼니 |
항-trem-1 항체 및 이의 용도
|
SI4122954T1
(sl)
|
2018-04-05 |
2024-07-31 |
Sun Pharmaceutical Industries Limited |
Novi analogi GLP-1
|
JP7442823B2
(ja)
|
2018-04-06 |
2024-03-05 |
シプルメット・ゲーエムベーハー |
治療用ペプチド及び治療用タンパク質の経粘膜送達のための薬学的組成物
|
WO2019200594A1
(zh)
|
2018-04-19 |
2019-10-24 |
杭州先为达生物科技有限公司 |
酰化的glp-1衍生物
|
EP3784312A1
(en)
|
2018-04-24 |
2021-03-03 |
DEKA Products Limited Partnership |
Apparatus and system for fluid delivery
|
TWI829687B
(zh)
|
2018-05-07 |
2024-01-21 |
丹麥商諾佛 儂迪克股份有限公司 |
包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
|
TW201946930A
(zh)
*
|
2018-05-15 |
2019-12-16 |
展旺生命科技股份有限公司 |
製備利拉魯肽衍生物的方法
|
US20210221867A1
(en)
|
2018-05-15 |
2021-07-22 |
Novo Nordisk A/S |
Compounds Capable of Binding to Melanocortin 4 Receptor
|
US10905738B2
(en)
|
2018-07-05 |
2021-02-02 |
Biozeus Desenvolvimento De Produtos Biofarmacêuticos |
Synthetic peptides, prodrugs, pharmaceutical compositions and uses
|
WO2020053414A1
(en)
|
2018-09-14 |
2020-03-19 |
Novo Nordisk A/S |
Bicyclic compounds capable of acting as melanocortin 4 receptor agonists
|
MX2021006505A
(es)
|
2018-12-03 |
2021-10-01 |
Antag Therapeutics Aps |
Analogos peptidicos del peptido insulinotropico dependiente de glucosa (gip) modificados.
|
WO2020187770A1
(en)
|
2019-03-15 |
2020-09-24 |
Diet4Life Aps |
Combination of dietary peptides
|
JP2022527812A
(ja)
|
2019-04-01 |
2022-06-06 |
ノヴォ ノルディスク アー/エス |
リラグルチドに対する抗体およびその使用
|
CN116082455A
(zh)
|
2019-07-10 |
2023-05-09 |
领导医疗有限公司 |
白细胞介素-23受体的肽抑制剂及其用于治疗炎症性疾病的用途
|
CN114630836A
(zh)
|
2019-08-27 |
2022-06-14 |
西兰制药第三特殊目的公司 |
补体抑制素类似物及其医学用途
|
KR20220075343A
(ko)
|
2019-09-03 |
2022-06-08 |
프로타고니스트 테라퓨틱스, 인코포레이티드 |
접합된 헵시딘 모방체
|
EP4054620B1
(en)
|
2019-11-06 |
2024-05-29 |
Novo Nordisk A/S |
Semaglutide in the treatment of alzheimer's dementia
|
JP2023502004A
(ja)
|
2019-11-07 |
2023-01-20 |
ノヴォ ノルディスク アー/エス |
Glp-1作動薬、sglt2阻害剤、およびn-(8-(2-ヒドロキシベンゾイル)アミノ)カプリル酸の塩を含む固形組成物
|
WO2021105393A1
(en)
|
2019-11-29 |
2021-06-03 |
Novo Nordisk A/S |
Processes for obtaining stable glp-1 compositions
|
CN111040022B
(zh)
|
2019-12-23 |
2021-12-14 |
万新医药科技(苏州)有限公司 |
针对胰高血糖素样肽-1受体、胰高血糖素受体、以及抑胃肽受体的三重激动剂
|
JP2023510218A
(ja)
|
2019-12-30 |
2023-03-13 |
ガン アンド リー ファーマスゥーティカルズ カンパニー リミテッド |
長時間作用型glp-1化合物
|
US11845808B2
(en)
|
2020-01-15 |
2023-12-19 |
Janssen Biotech, Inc. |
Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
|
MX2022008740A
(es)
|
2020-01-15 |
2022-09-23 |
Janssen Biotech Inc |
Peptidos inhibidores del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
|
US20230082544A1
(en)
|
2020-02-18 |
2023-03-16 |
Novo Nordisk A/S |
Pharmaceutical formulations
|
US20230110689A1
(en)
|
2020-03-30 |
2023-04-13 |
Zealand Pharma A/S |
Agonist combination
|
WO2021198196A1
(en)
|
2020-03-30 |
2021-10-07 |
Zealand Pharma A/S |
Glp-1/glp-2 dual agonists
|
US11478533B2
(en)
|
2020-04-27 |
2022-10-25 |
Novo Nordisk A/S |
Semaglutide for use in medicine
|
EP4142695A1
(en)
|
2020-04-29 |
2023-03-08 |
Novo Nordisk A/S |
Solid compositions comprising a glp-1 agonist and histidine
|
US20230173032A1
(en)
|
2020-05-07 |
2023-06-08 |
Frederiksberg Hospital |
Treatment of Hyperuricemia
|
JP2023541827A
(ja)
|
2020-09-07 |
2023-10-04 |
サイプルメド ゲーエムベーハー |
Glp-1受容体アゴニストの改善された医薬製剤
|
EP4222176A4
(en)
*
|
2020-09-30 |
2024-02-28 |
Beijing QL Biopharmaceutical Co., Ltd. |
POLYPEPTIDE CONJUGATES AND METHODS OF USE
|
IL302996A
(en)
|
2020-11-20 |
2023-07-01 |
Janssen Pharmaceutica Nv |
Compositions of peptide inhibitors of the interleukin-23 receptor
|
KR20230135586A
(ko)
|
2021-01-24 |
2023-09-25 |
마이클 데이비드 포레스트 |
Atp 합성효소 억제제 - 미용 및 치료 용도
|
FR3120189A1
(fr)
|
2021-03-01 |
2022-09-02 |
Farid Bennis |
Composition pharmaceutique pour une administration par voie orale d’un agoniste du récepteur du GLP-1
|
WO2023285334A1
(en)
|
2021-07-12 |
2023-01-19 |
Novo Nordisk A/S |
Novel fatty acid modified urocortin 2 derivatives and the uses thereof
|
WO2023012263A1
(en)
|
2021-08-04 |
2023-02-09 |
Novo Nordisk A/S |
Solid oral peptide formulations
|
JP2024533153A
(ja)
|
2021-09-03 |
2024-09-12 |
ジーランド ファーマ エー/エス |
投薬レジーム
|
CN118215478A
(zh)
|
2021-09-08 |
2024-06-18 |
盐野义制药株式会社 |
用于预防和治疗与抗肥胖作用有关的疾病的药物
|
WO2023192873A1
(en)
*
|
2022-03-28 |
2023-10-05 |
Bristol-Myers Squibb Company |
Macrocyclic immunomodulators
|
WO2024061919A1
(en)
|
2022-09-19 |
2024-03-28 |
Zealand Pharma A/S |
Combination therapy
|
TW202421654A
(zh)
|
2022-09-28 |
2024-06-01 |
丹麥商西蘭製藥公司 |
治療肥胖之方法
|
EP4345104B1
(en)
|
2022-09-30 |
2024-08-28 |
Bachem Holding AG |
Method for preparing liraglutide
|
TW202421645A
(zh)
|
2022-11-25 |
2024-06-01 |
丹麥商諾佛 儂迪克股份有限公司 |
如glp—1之肽治療劑的口服投與
|
WO2024141760A1
(en)
|
2022-12-30 |
2024-07-04 |
Algipharma As |
Compositions and methods to increase the systemic bioavailability of a polypeptide therapeutic agent undergoing oral administration
|
WO2024165571A2
(en)
|
2023-02-06 |
2024-08-15 |
E-Therapeutics Plc |
Inhibitors of expression and/or function
|